Immodulon Therapeutics announce EU Orphan Drug Designation for IMM-201 in the treatment of tuberculosis

On 20 September 2010, orphan designation (EU/3/10/786) was granted by the European Commission to Immodulon Therapeutics Ltd, United Kingdom, for heat-killed Mycobacterium vaccae (whole cell) for the treatment of tuberculosis.

Click here to view public summary